| 0 (0%) | 09-27 09:34 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.31 | 1-year : | 16.72 |
| Resists | First : | 12.26 | Second : | 14.31 |
| Pivot price | 10.75  |
|||
| Supports | First : | 10.27 |
Second : | 9.05 |
| MAs | MA(5) : | 11.77 |
MA(20) : | 10.5 |
| MA(100) : | 8.8 |
MA(250) : | 10.67  |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 90.3 |
D(3) : | 85.1 |
| RSI | RSI(14): 73.8 |
|||
| 52-week | High : | 21.85 | Low : | 4.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CRBP ] has closed below upper band by 17.6%. Bollinger Bands are 107.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.24 - 12.29 | 12.29 - 12.35 |
| Low: | 11.41 - 11.48 | 11.48 - 11.55 |
| Close: | 11.97 - 12.09 | 12.09 - 12.21 |
Tue, 23 Sep 2025
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Mon, 22 Sep 2025
100+ Patient Cancer Trial Results: Corbus to Present CRB-701 Data for Head & Neck, Cervical Cancers - Stock Titan
Mon, 22 Sep 2025
Forecast Cut: Can CRBP stock double in the next year - Portfolio Growth Summary & AI Powered Market Trend Analysis - خودرو بانک
Fri, 19 Sep 2025
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $55 - 富途牛牛
Tue, 16 Sep 2025
Corbus Pharmaceuticals (CRBP) Surges on New FDA Fast Track Designation - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 12 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 81.8 (%) |
| Shares Short | 1,160 (K) |
| Shares Short P.Month | 1,240 (K) |
| EPS | -4.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.3 % |
| Return on Equity (ttm) | -49 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.12 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -58 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -2.55 |
| PEG Ratio | 0 |
| Price to Book value | 1.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|